Neurovalens is a global health-tech company that creates non-invasive neurostimulation products to address some of the world’s greatest health challenges. Their medical device technology offers transdermal activation of the brainstem and hypothalamus, aiming to provide drug-free solutions to health epidemics.

Paul McGeoch

Jason McKeown

Neurovalens

Based in Belfast, Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world's greatest health challenges!

Modius is the first product from Neurovalens which successfully launched in August 2017 on Indiegogo. Modius was designed to help improve the lives of people who struggle with their weight by using neuro-technology to help make weight loss easier. 

Awards:

Winner: Health Category at the Future Planet Awards 2019
Winner: Best New Concept or Innovation at the 2018 Yahoo Sports Technology Awards 
Winner: 2018 CES Innovation Award
Winner: Start-Up of the Year at the 2018 Digital DNA Awards
Winner: Start-Up World Cup Northern Ireland Winner 2018
Winner: Randox Health Weight Management Product of the Year 2018
Winner: Business Eye Small Business Awards Healthcare Business of the Year 2018
Winner: Innovative Business of the Year at the BEFTA 2018 awards 
Placed 3rd at 2018 CES Last Gadget Standing
Finalist for Med Tech Innovator Award
Finalist in the Best Investment in the Disruptive Tech category at the UK Business Angel Investment Awards 2019

Invest Northern Ireland

MedTech Innovator

Techstart Ventures

ACF Investors

IQ Capital

Growth Finance Fund

Wharton Asset Management Company Limited

Clarendon Fund Managers

Future Fund

We're delighted to announce that the US Food & Drug Administration (FDA) have granted clearance for our Modius Sleep device for treating chronic insomnia.

Neurovalens CEO, Dr. Jason McKeown says:
“Having the Modius Sleep technology as a certified medical device for the treatment of chronic insomnia is a landmark step for the company as we focus on future growth in the U.S. market.”

READ MORE on this MassDevice article.
https://lnkd.in/eiymH8Vs

#medicaldevice #insomnia #medtech #innovation #technology #neuroscience #medical 

Our team are getting ready to be a part of LEAP 2024 from 4 - 7 March. Come and talk to us about Modius Sleep, our non-invasive and drug free treatment for Chronic Insomnia. #innovation #medicaldevice #medtech #technology #leap2024 Department for Business and Trade

We're delighted to have been shortlisted for two awards at this years Digital DNA. Looking forward to a great awards night! Best of luck to everyone shortlisted for the various categories. Some great companies, projects and people showcasing fantastic work. #innovation #belfast #medtech #modius

Meet Sinead

"Working for a company that develops non-invasive technology that has a positive impact on people’s health and quality of life is very motivating."

Sinead has been a part of the team at Neurovalens since September 2022. Take a minute or two to get to know what inspires and motivates her as she leads the clinical team.


Arab Health: Day 4

Last chance to try our FDA approved chronic insomnia treatment here at Arab Health Hall 2 G30!

Invest Northern Ireland Invest Northern Ireland - India, Middle East, Africa ABHI Department for Business and Trade Iain Hendrick Jason McKeown Patricia McKeown Sinead Watson

Metric
Company Name	Neurovalens
Symbol
MSH ID	COM:NEUROVALENS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare & Health Services
Country	GB
Stage
Employee Count	26
Website	neurovalens.com
LinkedIn	neurovalens
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	3.89K
Web Traffic Growth	0.07
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:NEUROVALENS

Neurovalens

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue